Published in J Nucl Med on June 30, 2014
In vivo imaging with antibodies and engineered fragments. Mol Immunol (2015) 0.98
uPAR-targeted multimodal tracer for pre- and intraoperative imaging in cancer surgery. Oncotarget (2015) 0.94
Preclinical evaluation of a novel CEA-targeting near-infrared fluorescent tracer delineating colorectal and pancreatic tumors. Int J Cancer (2015) 0.84
Preventing Radiobleaching of Cyanine Fluorophores Enhances Stability of Nuclear/NIRF Multimodality Imaging Agents. Theranostics (2017) 0.75
Hybrid intraoperative imaging techniques in radioguided surgery: present clinical applications and future outlook. Clin Transl Imaging (2017) 0.75
Dual-Modality Image-Guided Surgery of Prostate Cancer with a Radiolabeled Fluorescent Anti-PSMA Monoclonal Antibody. J Nucl Med (2014) 0.93
Monitoring Therapy Response of Experimental Arthritis with Radiolabeled Tracers Targeting Fibroblasts, Macrophages, or Integrin αvβ3. J Nucl Med (2015) 0.84
Phase 2 Study of Lutetium 177-Labeled Anti-Carbonic Anhydrase IX Monoclonal Antibody Girentuximab in Patients with Advanced Renal Cell Carcinoma. Eur Urol (2015) 0.83
Can 111In-RGD2 monitor response to therapy in head and neck tumor xenografts? J Nucl Med (2014) 0.82
Immuno-PET and Immuno-SPECT of Rheumatoid Arthritis with Radiolabeled Anti-Fibroblast Activation Protein Antibody Correlates with Severity of Arthritis. J Nucl Med (2015) 0.82
Graft revascularization is essential for non-invasive monitoring of transplanted islets with radiolabeled exendin. Sci Rep (2015) 0.80
111In-cetuximab-F(ab')2 SPECT and 18F-FDG PET for prediction and response monitoring of combined-modality treatment of human head and neck carcinomas in a mouse model. J Nucl Med (2014) 0.80
A Novel ¹¹¹In-Labeled Anti-Prostate-Specific Membrane Antigen Nanobody for Targeted SPECT/CT Imaging of Prostate Cancer. J Nucl Med (2015) 0.80
Therapy response monitoring of the early effects of a new BRAF inhibitor on melanoma xenograft in mice: evaluation of (18) F-FDG-PET and (18) F-FLT-PET. Contrast Media Mol Imaging (2014) 0.78
PET of EGFR with (64) Cu-cetuximab-F(ab')2 in mice with head and neck squamous cell carcinoma xenografts. Contrast Media Mol Imaging (2015) 0.76
Radionuclide and Fluorescence Imaging of Clear Cell Renal Cell Carcinoma Using Dual Labeled Anti-Carbonic Anhydrase IX Antibody G250. J Urol (2015) 0.76
Preclinical validation of (111)In-girentuximab-F(ab')2 as a tracer to image hypoxia related marker CAIX expression in head and neck cancer xenografts. Radiother Oncol (2017) 0.76
Preventing Radiobleaching of Cyanine Fluorophores Enhances Stability of Nuclear/NIRF Multimodality Imaging Agents. Theranostics (2017) 0.75
Liposomal Treatment of Experimental Arthritis Can Be Monitored Noninvasively with a Radiolabeled Anti-Fibroblast Activation Protein Antibody. J Nucl Med (2016) 0.75
Clinical application of FDG-PET/CT in metastatic infections. Q J Nucl Med Mol Imaging (2016) 0.75
In Vivo Imaging of Antileukemic Drug Asparaginase Reveals a Rapid Macrophage-Mediated Clearance from the Bone Marrow. J Nucl Med (2016) 0.75
Quantitative and longitudinal imaging of intramuscular transplanted islets of Langerhans with SPECT using [(123) I]IBZM. Diabetes Obes Metab (2016) 0.75
Early response monitoring with 18F-FDG PET and cetuximab-F(ab')2-SPECT after radiotherapy of human head and neck squamous cell carcinomas in a mouse model. J Nucl Med (2014) 0.75
Detection of Micrometastases Using SPECT/Fluorescence Dual-Modality Imaging in a CEA-Expressing Tumor Model. J Nucl Med (2017) 0.75
Comparison of three remote radiolabelling methods for long-circulating liposomes. J Control Release (2015) 0.75
Response Monitoring with [(18)F]FLT PET and Diffusion-Weighted MRI After Cytotoxic 5-FU Treatment in an Experimental Rat Model for Colorectal Liver Metastases. Mol Imaging Biol (2016) 0.75